Samsung Biologics삼성바이오로직스
207940 · KOSPI · ₩SBL · 삼성바이오로직스
₩1,487,000▲ ₩121,000 (8.86%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 53.8% | 55.2% | 50.4% | 48.8% | 48.9% | 46.3% |
| Operating margin | 50.0% | 45.4% | 29.0% | 30.1% | 32.8% | 34.3% |
| Net margin | 43.6% | 39.2% | 23.8% | 23.2% | 26.6% | 25.1% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −0.2% | +0.2% | +23.1% | +23.1% | +91.4% | — |
| Operating income growth | +9.9% | +56.8% | +18.5% | +13.2% | +83.1% | — |
| Net income growth | +11.2% | +64.7% | +26.3% | +7.5% | +102.8% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 25.1% | 19.4% | 10.4% | 9.1% | 11.4% | 7.9% |
| Return on assets | 16.7% | 12.6% | 6.5% | 5.3% | 6.5% | 4.9% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 51.3% | 48.4% | 59.0% | 63.2% | 84.6% | 59.7% |
| Net debt to equity | −14.6% | −7.2% | 0.4% | −4.0% | 1.7% | −14.8% |
| Current ratio | 179.7% | 174.0% | 143.2% | 132.8% | 154.4% | 255.0% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Samsung Biologics / 삼성바이오로직스 / 207940 / KRX:207940
Source: KRX statistical information